Mike Hodges

Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.

Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.

Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.

Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.